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Abstract
Background: Abnormalities of pre-mRNA splicing are increasingly recognized as an important
mechanism through which gene mutations cause disease. However, apart from the mutations in the
donor and acceptor sites, the effects on splicing of other sequence variations are difficult to predict.
Loosely defined exonic and intronic sequences have been shown to affect splicing efficiency by
means of silencing and enhancement mechanisms. Thus, nucleotide substitutions in these
sequences can induce aberrant splicing. Web-based resources have recently been developed to
facilitate the identification of nucleotide changes that could alter splicing. However, computer
predictions do not always correlate with in vivo splicing defects. The issue of unclassified variants
in cancer predisposing genes is very important both for the correct ascertainment of cancer risk
and for the understanding of the basic mechanisms of cancer gene function and regulation.
Therefore we aimed to verify how predictions that can be drawn from in silico analysis correlate
with results obtained in an in vivo splicing assay.
Results: We analysed 99 hMLH1 and hMSH2 missense mutations with six different algorithms.
Transfection of three different cell lines with 20 missense mutations, showed that a minority of
them lead to defective splicing. Moreover, we observed that some exons and some mutations show
cell-specific differences in the frequency of exon inclusion.
Conclusion:  Our results suggest that the available algorithms, while potentially helpful in
identifying splicing modulators especially when they are located in weakly defined exons, do not
always correspond to an obvious modification of the splicing pattern. Thus caution must be used
in assessing the pathogenicity of a missense or silent mutation with prediction programs. The
variations observed in the splicing proficiency in three different cell lines suggest that nucleotide
changes may dictate alternative splice site selection in a tissue-specific manner contributing to the
widely observed phenotypic variability in inherited cancers.
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Background
The precision and correctness of intron removal during
pre-mRNA splicing rely on the recognition of several dis-
crete elements some of which, as the splicing donor and
acceptor sites, are mostly invariant. However, many other
loosely defined cis-acting elements such as the polypyri-
midine tract, the branch site and several other sequences,
both exonic and intronic, may contribute to exon recogni-
tion. Recently, several reports have shown that exonic
sequences are able to regulate splicing proficiency, and
that nucleotide substitutions in these sequences, lead or
may lead to abnormal splicing or exon skipping [1,2].
Moreover, it has been demonstrated that aberrant splicing
can occur as a consequence of mutations that disrupt
exonic splicing enhancers (ESEs) or create exonic splicing
suppressors (ESSs) [reviewed in [3]]. Exonic splicing
enhancers have been identified on the basis of exon muta-
tions that block splicing, of computational comparison of
exon sequences, and of the selection of sequences that
activate splicing or that bind to specific regulatory pro-
teins, most notably the SR (serine-arginine rich) proteins.
Three web-based resources, ESEfinder [4,5], Rescue-ESE
[6,7], and PESX [8,9] have recently been developed to
identify putative ESEs responsive to the human SR pro-
teins and to predict whether exonic mutations disrupt
such elements. These algorithms have identified ESEs that
tend to colocalize with natural enhancers, and more fre-
quently in exonic sequences rather than in introns. In a
recent review, more than 50 nucleotide substitutions, that
had previously been reported to cause exon skipping in
vivo, were found to reduce or abolish at least one of these
computer-identified ESEs [10]. Therefore, a significant
number of disease-associated point mutations or poly-
morphisms may lead to aberrant splicing. However,
enhancer and silencer elements can be juxtaposed in spe-
cific exonic regions. Thus, efficient splicing is the result of
a plethora of quite complex interactions mediated by dif-
ferent splicing factors, each binding to its proper target
sequence. We have recently investigated several mutations
altering splicing in the MLH1 gene whose mutations are
responsible for Hereditary Non Polyposis Colorectal Can-
cer (HNPCC, MIM 114500) [11,12]. Patients with
HNPCC usually have a family history of early onset of
synchronous and metachronous colorectal cancers and an
elevated risk of several other extracolonic malignancies,
mainly of the endometrium, stomach, hepato-biliary tract
and ovary. The disease is caused by germline mutations of
genes within the DNA mismatch repair (MMR) pathway.
Nearly 90% of families with an identified genetic defect
harbor mutations in either MLH1  (MIM 120436) or
MSH2  (MIM 609309), [13,14]. The InSIGHT database
[15], accessed in March 2003, lists a total of 382 different
MLH1 and MSH2 mutations. While the majority of these
are either nonsense or frameshifting alterations with an
obvious pathogenic influence on the resultant protein,
26% of the alterations listed in the database are missense
mutations and therefore their consequences on biological
functions are assumed to rely on the principle that the sin-
gle change introduced in the amino acid sequence impairs
the biological function or the structure of the encoded
protein. A recent work [16] has demonstrated that patho-
genic missense mutations in the hMLH1 and hMSH2
genes, in contrast to polymorphic variants, tend to colo-
calize in ESE sequences.
On the basis of all the above evidence, we decided to eval-
uate the 99 hMLH1/hMSH2 missense mutations listed in
the InSIGHT database with the currently available ESE
prediction programs. We next investigated the conse-
quences of 20 exonic missense mutations with different
predicted effects on putative enhancer and suppressor
sequences. We found that the splicing behaviour of these
mutations cannot be evaluated only on the basis of their
predicted localization in ESE sequences.
To further extend our analysis, we assessed the effects of
the 20 missense mutations in three different mammalian
cell lines. We observed that some nucleotide changes
affect splicing with a different degree of severity in differ-
ent cellular backgrounds.
Results
ESEfinder, RescueESE and PESX identify non overlapping 
ESE motifs
A recent survey of all the missense mutations and neutral
polymorphisms reported in the InSIGHT mutation data-
base for the hMLH1 and hMSH2 genes [15] indicates that
missense mutations, but not neutral polymorphisms,
tend to occur where ESE sequences are localized [16]. Of
the 99 different missense mutations reported in this
paper, 50 were localized in ESE sequences identified by
ESE finder. We analyzed the same mutation data set with
RescueESE and PESX that found respectively 40 and 41
mutations as lying in ESE sites [see additional file 1]. A
total of 7 mutations were identified as lying in ESE sites by
all the three algorithms. Among these, only 2 caused the
same type of predicted change (ie all programs predicted
no change, or creation/addition of novel ESE motifs, or
disruption of ESE sites). However, in only one case all the
three algorithms equally predicted ESE sites disruption
without the concurrent creation of novel ESE sites. Since
in our previous work we found that the abrogation of ESE
motifs identified by the first two algorithms does not
always lead to a splicing defect [12], we selected 20
hMLH1 and hMSH2 mutations with different predicted
effects on ESEs (table 1). We examined their consequences
in a splicing assay we already had available [11] and pre-
viously reported to faithfully recapitulate in vivo splicing
[17-19]. The criteria for selection were that the mutations
should create or abolish one or more ESE sites accordingB
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Table 1: Pathogenic Missense Mutations analyzed in the splicing assay
NNSPLICEe SpliceSite 
Finderf
Mutationa Exon ESEfinderb Rescue ESEc PESXd SA SD SA+BPS SD GENSCAN Exon P-valueg Dist. from the 
nearest SS
Exon size 
(bp)
Mutation 
effect on 
splicing
hMSH2
A308G 2 SRp40 3.05>0 0 0 0.99 1 170.8 85.6 0.998(0.998) -58 155 =
A593G 3 SF2 3.67>2.80 +SRp40 -2/2 0 0.98 1 161.5 94.2 0.861(0.861) -52 279 =
C806T 5 SRp55 2.67>0 -1/1 +1/0 PESS 0.96 0.92 NI 79.9 0.987(0.985) +14 150 ↓
C815T 5 SF2 3.2>0 SRp55 2.7>0 0 -1/1 PESS 0.96 0.92 NI 79.9 0.987(0.985) +23 150 ↓
G965A (3) 6 SC35 3.39>3.03 SRp40 5.72>3.34 0 +1/0 PESE 0.98 0.98 187.8 88.7 0.999(0.999) +24 134 =
G1012A 6 SF2 2.2>0 SC35 2.6>0 SRp404.3>0 +2/5 -1/1 PESE 0.98 0.98 187.8 88.7 0.999(0.999) -64 134 =
G1516T 10 SC35 5.44>4.79 + SC35 0 -4/4 PESE NI 0.60 150.5 72.8 0.991(0.991) +6 151 ↓
G1571C 10 SRp55 3.3>0 + SC35 0 0 NI 0.60 150.5 72.8 0.991(0.991) +61 151 =
C1600T 10 SRp55 3.4>0 0 +1/0 PESS NI 0.60 150.5 72.8 0.991(0.991) -61 151 ↓
hMLH1
G199A (8) 2 SF2 4.26>2.34 +1SF2 +1 SC35 0 0 0.86 1 180.4 92.2 0.790/0.789 -8 91 =
G200A (2) 2 SF2 4.26>0 -1/7 0 0.86 1 180.4 92.2 0.790/0.789 -7 91 =
T320G 4 SRp55 3.3 >0 + SF2 2.8 +4/1 +3/0 PESE 1 0.88 155.6 69.7 0.987/0.990 +14 74 =
G731A 9 SRp40 3.7>0 0 -3/3 PESS 0.88 0.96 156.4 78.3 0.338/0.205 term +54 113 =
C793T (2) 10 SRp40 3.85>4.2 0 0 0.99 0.93 167.8/
171
81.0 NI/NI +4 94 =
C842T 10 SF2 3.2>0 SC35 2.6>0 SRp55 
4.7>3.1+SRP55
0 = 1 PESS 0.99 0.93 167.8 81.0 NI/NI -42 94 ↓
G1569T 14 0 -3/3 0 0.98/
0.97
0.99 182.3 85.6 0.912/0.976 +11 109 =
T1958G 17 SF2 2.1= SRp55 3.5>0 + SF2 0 0 NI 0.91 166.6 90.0 0.836/0.877 -31 93 ↑
C1961T 17 SF2 2.1>0 SRp55 = +SC35 0 0 NI 0.91 166.6 90.0 0.836/0.828 -28 93 =
A1963G 17 SF2 2.1> 0 SRp55 3.5>0 -1/2 +1/0 PESE NI 0.91 166.6 90.0 0.836/0.857 -26 93 ↑
G1976C 
(3)
17 SRp40 4.3>5.15+SC35 0 0 NI 0.91 166.6 90.0 0.836/0.490 -13 93 ↓
a in parenthesis the number of families/cases in the database presenting the mutation.
b effect of the mutation on the scores as predicted by the algorithm.
c number of ESE motifs added or abrogated from the mutation/number of ESE motifs in the normal allele.
d number of enhancer (PESE) or suppressor (PESS) sequences added or abrogated from the mutation/number of PESE or PESS in the normal allele.
e SA = splice acceptor, SD = splice donor, NI = not identified as corresponding splicing site by the program, in italics are indicated the suboptimal scores.
f SA+BPS = splice acceptor + branch point sites, NI = not identified as corresponding splicing site by the program, in italics are indicated the suboptimal scores.
g in parenthesis the score for the wild type allele; term = the exon is recognized as a terminal exon.
In bold the mutations significantly altering splicing: = no change in exon inclusion; ↑ = increase in exon inclusion; ↓ = increase in exon skipping.BMC Genomics 2006, 7:243 http://www.biomedcentral.com/1471-2164/7/243
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to the predictions of at least one algorithm. All the mini-
gene constructs were assembled in the pSPL3 vector (for
details see fig. 1 and methods).
Analysis of 20 hMLH1 and hMSH2 missense mutations 
shows that mutations altering splicing are situated 
preferentially in exon subjected to alternative splicing
Figure 2A,B shows the results of the RT-PCR experiments
on Cos-7 cells transfected with the 20 different mutations
analyzed and their respective normal controls consisting
of the corresponding non mutated exon. As a positive
control for the splicing assay we used the C6354T muta-
tion in exon 51 of the FBN1 gene, which has already been
reported to cause exon skipping both in vivo and in vitro
[20]. Overall, the results of this analysis showed that even
if all the mutations fall in ESE sites predicted from either
ESEfinder, or RescueESE or PESX, less than half of them
led to splicing alterations. In particular, aberrant splicing
should be expected whenever a mutation abrogates one or
more ESE sites without creating novel sequence motifs
recognized by other SR proteins. However, even when the
mutations were clustered in a small exonic region, they
demonstrated a splicing proficiency not always corre-
sponding to the one expected on the basis of the algo-
rithms predictions. Paradigmatic results were obtained
from the splicing assay of the four different hMLH1 muta-
tions T1958G, C1961T, A1963G and G1976C, that all lie
in exon 17. The first two lead to concurrent creation of
Schematic representation of the reporter construct used in the splicing assay Figure 1
Schematic representation of the reporter construct used in the splicing assay. Structure of the chimeric minigene 
used in all the transfection experiments. Patterned and white boxes indicate the pSPL3 HIV-tat exonic sequences and the 
human hMLH1/hMSH2 sequences. Arrows show the primers used in the RT-PCR experiments. The indicated XhoI and BamHI 
sites are those used to clone all the constructs. MCS = multi cloning site, Amp = ampicillin resistance gene, M = mutated con-
struct, Wt = corresponding normal exon.
hMLH1/hMSH2 minigenes
SDv SAv Xho I Bam HI
SA2 SD6
MCS
pSPL3
Amp
M
Bam HI Xho I
Wt
Bam HI Xho IBMC Genomics 2006, 7:243 http://www.biomedcentral.com/1471-2164/7/243
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novel ESE sites, in addition to those already present in the
wild type sequence, and disruption of one ESE motif for
the SRp55 and one for the SF2/ASF splicing factor, respec-
tively (see figure 3 and table 1). In fact, these two muta-
tions did cause only slight changes to the ratio of exon
inclusion compared to the normal exon (fig. 2). The
A1963G mutation abrogated the same two ESE motifs, as
well as one of the two ESEs predicted by RescueESE, but
A1963G while not creating any novel ESE sequence for
ESEfinder and RescueESE, did generate an ESE sequence
according to PESX (fig. 3). The G1976C mutation added a
novel ESE site to the one already identified by ESEfinder
as present in the wild type sequence, while no ESE motifs
are predicted in either the normal or the mutated allele by
both RescueESE and PESX. Surprisingly, only the G1976
mutation dramatically altered the rate of exon inclusion
Effects of the hMLH 1 and hMSH2 mutations on exon inclusion Figure 2
Effects of the hMLH 1 and hMSH2 mutations on exon inclusion. Results of the splicing assay with the different 
hMLH1(A) and hMSH2(B) mutated constructs. Numbering is relative to the nucleotide position in the ORF. Cos-7 cells were 
transfected with 1 μg of the indicated mutant minigene variants or the corresponding wild-type exon, RNA was extracted, 
reverse transcribed, and amplified with primers SD6 and SA2. The RT-PCR products were resolved on GeneGel Excel, stained 
with ethidium bromide and quantitated with an image analyzer (see methods). V = vector only; Mw = size standard. The black 
arrowhead represents the exon skipped product. The percentage of exon inclusion is indicated above each lane. The white 
asterisks show the splicing product deriving from use of an internal cryptic donor site. Below the gel are reported the predic-
tions for the three algorithms: = no change; + the mutation creates an ESE or abrogates an ESS sequence; - the mutation cre-
ates an ESS or abrogates an ESE sequence; 0 the mutations is not localised in, and does not create or disrupt any regulatory 
sequence. (C, D) Graphic representation of the splicing assay results. The average of percent exon inclusion is reported in the 
y-axis and represents the mean of two independent transfections done in triplicate for each construct (x-axis). White bars are 
used for normal alleles, patterned for mutated constructs. Mutations within the same exons are grouped together and with 
their corresponding normal exon. Error bars represent standard deviation. The mutated constructs causing significant differ-
ences when data were analysed using Student's t test are underlined (* = P < 0.05, ** = P < 0.01,*** = P < 0.001).
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in the splicing assay (figures 2, 3 and table 1), while the
A1963G mutation, which should have been responsible
for the most severe effect on splicing, according to both
ESEfinder and RescueESE, instead caused an increase in
the exon inclusion rate.
It has to be said that the splicing assay demonstrated that
exon 17 inclusion was only partial for all of these muta-
tions, as it was for the wild type exon. This situation mim-
ics what has been observed in vivo for hMLH1, since
alternative splicing of exon 17, where the four mutations
are located, has been reported by several authors [21]. In
addition, mutation G1976C and its cognate G1976A were
already reported to lead to aberrant splicing in vivo [22].
Since this mutation does not alter any recognized
enhancer or suppressor sequence, this data lend further
support to the hypothesis of the presence of a different
auxiliary element in this exonic region [23]. The other 5
mutations that in our splicing assay did change signifi-
cantly the ratio of exon inclusion were C842T in hMLH1
exon 10, C806T and C815T in hMSH2 exon 5, and the
two mutations in hMSH2 exon 10, G1516T and C1600T
(fig. 2). The splicing behaviour was correctly predicted by
PESX and ESEfinder for four of these five, while Rescue
ESE correctly predicted the consequences on splicing of
the only mutation localizing in a sequence identified as a
splicing enhancer by this algorithm. Significantly all of
these five mutations, as those in hMLH1 exon 17, lie in
exons that have been reported to be alternatively spliced
in vitro [21,24].
In conclusion, summarizing the results of the in vivo
splicing analysis, 8 of the 20 mutations investigated
caused a significant change in the splicing pattern and 6
led to a decrease of at least 50% of the rate of exon inclu-
sion when compared to the wild type allele. The splicing
consequences of these 8 mutations, correlated with ESE-
finder predictions in 4 cases, 6 mutations were localized
in ESE or ESS sequences identified by PESX which cor-
rectly predicted the splicing behaviour of 5 of them, while
only 3 lie in ESE sequences recognized by RescueESE
whose prediction correlated with the splicing behaviour
of 2 of these 3. Furthermore, when exons were included or
skipped completely in our assay they appeared to be
insensitive to any change affecting ESE or ESS sequences.
The higher correlation level of PESX predictions with the
splicing pattern probably relies on the fact that, PESX dif-
ferently from ESE finder and Rescue-ESE predicts not only
exonic enhancer sequences but also those with a suppres-
sor effect. Overall, the results of our splicing assay were
Effects of the hMLH 1 exon 17 mutations on ESE sequences identified by the different algorithms Figure 3
Effects of the hMLH 1 exon 17 mutations on ESE sequences identified by the different algorithms. The complete 
sequence of exon 17 is shown (exonic sequence in capital bold). Numbering is relative to the nucleotide position in the ORF. 
The four exon 17 mutations are shown, wild type sequence underlined. The consequences of the four mutations on the pre-
dicted motif scores identified by ESEfinder, RescueESE and PESX are shown below.BMC Genomics 2006, 7:243 http://www.biomedcentral.com/1471-2164/7/243
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comparable to the in vivo splicing profile of hMLH1 and
hMSH2, since exons normally presenting alternative splic-
ing all showed an inclusion rate ranging from null to
73%, but never complete.
Analysis of the 20 mutations with NNSPLICE, SpliceSite 
finder and GENSCAN
The results of the transient transfection experiments dem-
onstrated that the splicing pattern for the 20 selected
mutations cannot be precisely predicted on the basis of
ESEfinder, RescueESE and PESX computations. We then
decided to investigate their effects using additional in sil-
ico resources, namely the two splice site prediction pro-
grams NNSPLICE [25] and SpliceSite finder [26], and the
gene prediction program GENSCAN [27]. This latter pro-
gram has been reported to reliably predict the splicing
consequences of 4 different nucleotide substitutions in
MLH1 and BRCA1 genes that caused an in vivo RNA splic-
ing defect [28]. The results obtained with these further
computer analyses are reported in table 1. Of the 99 dif-
ferent missense mutations listed in the InSIGHT mutation
database, only 6 led to a relatively large change (mean
change in probability p = 0.230, standard deviation ±
0.102, see additional file 1) of GENSCAN score. Of these,
2 were in terminal exons, 2 were in the splicing junctions
(therefore having clear consequences on splicing), while 2
were located in internal exons, far from the splicing sites.
These latter mutations, G731A and G1976C, were both
analyzed in our assay. The hMLH1 G731A mutation, that
causes a consistent change of GENSCAN score (see table
1), is in the hMLH1 exon 9 that is not recognized as an
internal exon by GENSCAN and is skipped in the splicing
assay regardless of the presence of the mutation. Finally
mutation G1976C which caused the largest decrease of
GENSCAN scores did lead to a significant increase in exon
skipping (fig. 2A,B). On the contrary, none of the muta-
tions analyzed introduced any significant change in the
splicing donor (SD) and acceptor (SA) site scores identi-
fied by NNsplice or in those calculated by SpliceSite finder
for the SD and SA+BPS sites.
Alternative splicing and some mutations show a cell line 
specific effect
To investigate the possibility that some mutations may
show tissue-specific differences, we used the same con-
structs analyzed in Cos-7 cells to transfect two other cell
lines, namely the cervical adenocarcinoma-derived HeLa
cell line and the hepatocellular carcinoma cell line Hep-
3B. The RT-PCR results on RNA extracted from these two
cell lines 48 hours after transfection with the different
mutated and normal constructs demonstrated a variable
level of inclusion for the exons already reported to be
alternatively spliced in vivo (exons 2,3,5,6 and 10 for
hMSH2, exons 10 and 17 for hMLH1).
In particular, in the HeLa and Hep-3B cells, the hMSH2
exon 10 inclusion level was decreased by 30% and 45%,
respectively, compared to the level observed in Cos-7 cells
(fig. 4A,B). The hMSH2 exon 5 and the hMLH1 exon 10
both showed a large increase in the rate of exon inclusion
in HeLa cells compared to Cos-7 (60 and 115%, respec-
tively). Finally, the hMLH1 exon 17 inclusion was nearly
halved in HeLa cells and decreased to one third in Hep-
3B.
Splicing assay mimics in vivo alternative splicing and varies in  human cell lines Figure 4
Splicing assay mimics in vivo alternative splicing and 
varies in human cell lines. (A) Results of the splicing assay 
following transfection with constructs harboring the different 
hMSH2 and hMLH1 normal exons. Cos-7 (C), Hep-3B (Hp) 
and HeLa (He) cells were transfected with 1 μg of the indi-
cated wild-type exon, RNA was extracted, reverse tran-
scribed, and amplified with primers SD6 and SA2. The RT-
PCR products were resolved on GeneGel Excel, stained with 
ethidium bromide and quantitated with an image analyzer 
(see methods). Mw = size standard. The percentage of exon 
inclusion is indicated below each lane. (B) The graph shows 
the average of percent exon inclusion in the three different 
cell lines when transfected with the contructs containing the 
different normal exons (y-axis), representing the mean of 
two independent transfections done in triplicate for each 
construct (x-axis). Error bars represent standard deviation. 
The data were analysed using Student's t test (* = P < 0.05, ** 
= P < 0.01, *** = P < 0.001).
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We next analyzed the consequences on splicing of the
mutations that had been able to cause splicing abnormal-
ities when tested in Cos-7 cells. Although for the majority
of the mutations analyzed the effects on the splicing pro-
ficiency were similar to those observed in Cos-7 cells, for
the mutations situated in the alternatively spliced exons
there was an evident variability in the level of inclusion.
The most dramatic change was observed for the mutations
G965A and G1012A in exon 6 of the hMSH2 gene. When
transfected in Cos-7 cells, these two mutations did not
cause a change in the rate of exon inclusion compared to
the normal allele, but in both Hep-3B and HeLa cells,
G1012A led to a 40% decrease in exon inclusion (fig.
5A,B). Since this mutation disrupts all three ESE motifs
identified by ESEfinder, it is possible that local changes in
SR protein levels in both these two cell types cause the
G1012A mutation to have an overt effect on splicing in
Hep-3B and HeLa cells but not in Cos-7. Likewise, the
hMSH2 exon 10 mutations G1516T and C1600T showed
a decrease in the exon inclusion level by 70% in Cos-7 and
by 28% in Hep-3B cells, but a very weak effect in the HeLa
cellular background. The G1571C mutation in the same
exon had no effect in Cos-7 cells, while leading to a 60%
exon inclusion increase in Hep-3B and to a slight exon
inclusion increase in HeLa (fig. 5C,D). A further example
of cell-specific effects was observed for the four hMLH1
mutations in exon 17. All four mutations in this exon had
a more severe effect when transfected in HeLa cells, com-
pared to the consequences on splicing observed in Cos-7
and Hep-3B (fig. 5E,F). In fact, the G1976C mutation con-
sistently reduced the ratio of exon inclusion in all the
three cell lines but led to almost complete exon skipping
exclusively in HeLa cells. C1961T caused a slight increase
in exon inclusion only in HeLa cells, while T1958G and
A1963G both increased exon 17 inclusion levels in all
three cell lines, with a higher rate of inclusion in HeLa
cells.
Discussion
Evaluation of putative splicing mutations by computer 
programs
Recent reports have shown that mutations in the coding
region disrupting sequences recognized by splicing regu-
lators such ESE, ESS or the recently identified composite
exonic regulatory elements (CERES) [29], can be consid-
ered an additional mutation mechanism leading to dis-
ease in humans. This finding is particularly important for
genetic counselling in HNPCC, where the pathogenicity
assessment of any nucleotide substitution is crucial to cor-
rectly predict cancer risk.
Several experimental or computational approaches, aim-
ing to identify regulatory sequence motifs whose muta-
tions are predicted to alter splicing, have been developed.
All of these experimental approaches share the functional
evaluation of short random oligomer sequences in
reporter systems represented by short exons with weak
splicing sites. However, these functional assays have been
performed in highly purified in vitro systems that may not
fully reflect in vivo splicing conditions. In addition, these
sequences with a putative enhancer activity have not been
tested in their natural context, which can be represented
by clusters of several overlapping motifs with complex
and often antagonistic interactions as already demon-
strated for the CFTR gene [29]. As a consequence, the ESE
sequences predicted by the algorithms developed using
these strategies tend to overlap with true splicing enhanc-
ers only when they lie in short, weakly defined exons.
However, human exons are on average 130 bp in size and
99% of them possess strong, well-defined splicing sites.
The preferential colocalization of pathogenic mutations
with ESE sequences as compared with neutral polymor-
phisms has been reported [16] but a systematic evaluation
of missense mutations and neutral polymorphisms pre-
dicted to alter splicing have not been performed.
The splicing analysis we have performed suggests that the
ESEs predicted by these algorithms are likely to act as real
enhancer when mutations fall in short loosely defined
exons that are more frequently expected to contain
sequences promoting exon inclusion in the mature tran-
script. In fact, most of the nucleotide changes associated
with altered splicing, lie in exons averaging 67 bp in size,
well below the 130 bp dimension of a typical human exon
[10]. Furthermore, our data are supported from recent
work [30] that shows that the ability to function as an
enhancer is dependent on its natural surrounding envi-
ronment and ESE position in the exon.
Hence, thorough in silico analysis and the knowledge of
the alternative splicing profile of the gene of interest may
contribute to assign pathogenic significance. In this study
we have analyzed all the pathogenic missense mutations
reported in the HNPCC mutation database, with three
ESE prediction programs (ESEfinder, Rescue ESE and
PESX), then with two splice site prediction programs
(NNSPLICE and SpliceSite finder) and a gene prediction
program (GENSCAN). Among the 99 mutations exam-
ined, 72 changed ESE motifs scores predicted by ESE-
finder, RescueESE or PESX. Of these, 20 were analyzed for
their splicing proficiency with an in vivo splicing assay we
had already used in the past. Not surprisingly, the major-
ity of mutations tested (12 of 20) did not alter the normal
constitutive or alternative splicing pattern. Indeed, most
exons in the hMSH2 and hMLH1 genes are large and well
defined with few notable exceptions. It is worthy of note
that all of the 8 mutations that did affect splicing in the
assay we used fall in exons for whom alternative splicing
has been reported, or showing suboptimal splice siteBMC Genomics 2006, 7:243 http://www.biomedcentral.com/1471-2164/7/243
Page 9 of 12
(page number not for citation purposes)
scores when analyzed with NNSPLICE and SpliceSite
finder (hMSH2 exons 5 and 10, hMLH1 exon 17), or in
exons not recognized by GENSCAN (hMLH1 exon 10).
Our data and a recent functional analysis performed on
hMLH1 missense mutations [31] suggest that most path-
ogenic substitutions in MMR genes impair the biological
function of the protein rather than splicing proficiency.
Furthermore, when tested on mutations far from the splic-
ing site, the prediction power of ESEfinder revealed a sen-
sitivity lower than that recently reported [32].
Differences in the alternative splicing profile and in the 
mutations effects between cell types
A large amount of data is accumulating, supporting the
hypothesis that the global alternative splicing profile
reflects tissue identity, and that alternative splicing acts
independently on different sets of genes, defining tissue-
specific expression profiles. The expression levels of antag-
onistic splicing factors, such as hnRNPA1 and SF2/ASF,
have been shown to affect splice site selection [33], and
colon cancer progression [34]. Thus, if a tissue-specific
Splicing effects of mutations in hMSH2 exons 6 and 10, and hMLH1 exon 17 in the three different cell lines Figure 5
Splicing effects of mutations in hMSH2 exons 6 and 10, and hMLH1 exon 17 in the three different cell lines. Pan-
els A (hMSH2 exon 6), C (hMSH2 exon 10), E (hMLH1 exon 17) show the RT-PCR results of the splicing assay performed in 
the three cell lines transfected with 1 μg of the mutated and corresponding normal constructs. 48 hours after transfection, 
RNA was extracted, reverse transcribed and amplified with primers SD6 and SA2. The RT-PCR products were resolved on 
GeneGel Excel, stained with ethidium bromide and quantitated with an image analyzer (see methods). Mw = size standard. The 
percentage of exon inclusion is indicated below each lane. The graphs (B for hMSH2 exon 6 and its mutations, D for hMSH2 
exon 10 and its mutations, F for hMLH1 exon 17 and its mutations) show the averages of percent exon inclusion (y-axis) in the 
three different cell lines when transfected with the constructs containing the different mutated or normal exons, representing 
the mean of two independent transfections done in triplicate for each construct (x-axis). Error bars represent standard devia-
tion. The data were analysed using Student's t test (* = P < 0.05, ** = P < 0.01, *** = P < 0.001).
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regulation of pre-mRNA splicing exists and depends on
local differences of the regulatory factors concentration, it
is likely that some mutations may show tissue- or cell-spe-
cific effects. However, the presence of such variability has
not been thoroughly investigated. We therefore decided to
investigate whether the mutations analyzed in our in vivo
assay showed a different splicing profile in three different
cell lines. An invariant pattern of splicing was observed for
the constitutive exons but intriguingly for the mutations
lying in alternative exons, both the mutated and the nor-
mal alleles showed variability in the ratio of exon inclu-
sion. In fact, differences were observed both in the level of
inclusion of alternative normal exons and in the magni-
tude of changes caused by mutations localizing in these
exons (figs. 4, 5). These results confirm the recent findings
based on microarray analysis, demonstrating that human
tissues show rather divergent patterns of alternative splic-
ing, yet correlated with differences in the splicing factor
expression across tissues [35]. As a consequence, the net
results of a mutation altering the splicing pattern might
derive from local changes in the concentration of splicing
modulators.
Both MLH1 and MSH2 genes show extensive alternative
splicing with as many as eight different isoforms reported
for MLH1 and seven for MSH2 [21,24]. More than half of
these alternative isoforms are predicted to give rise to
truncated proteins. Some of these isoforms have been
reported to be expressed also in normal individuals and
tissues [21] but no studies have assessed quantitatively the
expression of these splice variants at the RNA level.
Our systematic analysis of different mutations in the
hMLH1 and hMSH2 genes in three human cell lines,
shows that a single mutation can provoke quite diverse
consequences in different cell types. Similar results were
obtained when the three cell lines were transfected with
exons reported to be alternatively spliced in vivo, suggest-
ing that cell specificity may nudge splice selection toward
a variable ratio of exon inclusion vs skipping. In rapidly
replicating tissues immunohistochemical analysis have
demonstrated that MLH1/MSH2 proteins are highly
expressed [36,37]. Therefore, in tissues where the require-
ments for protection from DNA replication errors are
inherently higher, the relative abundance of isoforms with
different MMR proficiency may be critical in determining
the time and the frequency of cancer pathogenesis.
Conclusion
Our study indicates that missense mutations in MLH1
and MSH2 are likely to affect splicing only when located
in weak alternative exons. However when they do so, they
might modulate in a tissue specific manner cancer onset
and its phenotypic manifestations.
Methods
Generation of datasets and computational analysis
The 99 missense mutations analyzed were annotated in
the InSIGHT database accessed in March 2003. All the
exons of the MLH1 and MSH2 genes with the adjacent
intronic sequences included in the construct used for the
splicing assay (see below) were analyzed using the five
software packages ESEfinder, RescueESE, NNSPLICE,
SpliceSiteFinder, GENSCAN, and PESX. Only for GENS-
CAN analysis, was the whole genomic contig sequence of
the MLH1 (NCBI accession number NT_022517.17) and
MSH2  (NCBI accession number NT_022184.14) genes
used to generate computer predictions. In all cases the
score values were calculated for both normal and wild
type allele.
Mutagenesis and plasmid construction
Wild-type sequences of each exon used in the assay, as
well as 50–160 nucleotides each side of flanking intronic
sequences, always including the putative branch point site
(identified with SpliceSite Finder), were amplified from
human genomic DNA, using XhoI and BamHI tagged
primers (primer sequences available on request). The 20
single nucleotide substitutions were introduced by over-
lap extension PCR with primers tagged with XhoI and
BamHI restriction sites. All the 20 missense mutations
analyzed and the respective controls consisting of the cor-
responding wild type exons in which the mutations were
located, were cloned in the pSPL3 vector (fig. 1). All plas-
mid constructs were confirmed by DNA sequencing and
in all cases the nucleotide substitution introduced repre-
sented the only difference between the mutated construct
and its corresponding normal control.
Transient transfection and analysis of RNA splicing 
pattern
All the transfections were performed in 24 well plates at
approximately 90% cell confluence using Lipofectamine
2000 (Invitrogen). All the cell lines were grown in DMEM
supplemented with 10% fetal bovine serum and 5 mM
glutamine. Cells were subjected to a maximum of two pas-
sages in culture before transfection. For each transfection
1 μg of total plasmid DNA were used. cDNA synthesis and
PCR were performed as previously reported [12], with the
exception that 25 cycles were used to maintain the PCR in
the logarithmic phase. For gel analysis the PCR reactions
were resolved on precast polyacrylamide gels (GENEGEL
EXCEL AP Biotech) stained with ethidium bromide. Gel
images were obtained and the results quantitated using a
Bio-Rad Versadoc 4000 imager system and Quantity One©
software. The identity of all the RT-PCR products was con-
firmed by sequencing.BMC Genomics 2006, 7:243 http://www.biomedcentral.com/1471-2164/7/243
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Note added in proof
Recently an upgrade of the alternative splicing database
(ASD) has been published [38]. It is a collection of litera-
ture-based data set containing useful tools for splicing
related analysis such as sequences and properties of alter-
natively spliced exons, characterization of observed splic-
ing regulatory elements, a collection of minigene
constructs and many more features.
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